Tillkännagivande • Aug 18
Lippo Limited to Report First Half, 2025 Results on Aug 28, 2025 Lippo Limited announced that they will report first half, 2025 results on Aug 28, 2025 Tillkännagivande • May 22
Lippo Limited, Annual General Meeting, Jun 23, 2025 Lippo Limited, Annual General Meeting, Jun 23, 2025, at 11:45 China Standard Time. Location: concord room, 8th floor, renaissance harbour view hotel hong kong, 1 harbour road., wanchai Hong Kong Tillkännagivande • Mar 18
Lippo Limited to Report Fiscal Year 2024 Results on Mar 28, 2025 Lippo Limited announced that they will report fiscal year 2024 results on Mar 28, 2025 Board Change • Dec 30
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Non-Executive Director Min Yen Goh was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 30
First half 2024 earnings released: HK$0.89 loss per share (vs HK$0.005 profit in 1H 2023) First half 2024 results: HK$0.89 loss per share (down from HK$0.005 profit in 1H 2023). Revenue: HK$410.0m (up 6.0% from 1H 2023). Net loss: HK$436.9m (down HK$439.7m from profit in 1H 2023). New Risk • Sep 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (€43.9m market cap, or US$48.7m). Reported Earnings • Aug 30
First half 2024 earnings released: HK$0.89 loss per share (vs HK$0.005 profit in 1H 2023) First half 2024 results: HK$0.89 loss per share (down from HK$0.005 profit in 1H 2023). Revenue: HK$410.0m (up 6.0% from 1H 2023). Net loss: HK$436.9m (down HK$439.7m from profit in 1H 2023). Tillkännagivande • Aug 15
Lippo Limited to Report Q2, 2024 Results on Aug 27, 2024 Lippo Limited announced that they will report Q2, 2024 results on Aug 27, 2024 Tillkännagivande • Jun 09
Lippo Limited Announces Chief Executive Officer Changes, Effective from 7 June 2024 The Board of Directors of Lippo Limited announce that Mr. John Luen Wai Lee will be re-designated from the Managing Director and Chief Executive Officer to the Deputy Chairman of the Company with effect from 7 June 2024. He remains as an executive Director of the Company. The company announce that Mr. Kwok Fai Lee will be appointed as Chief Executive Officer of the Company with effect from 7 June 2024. Mr. Kwok Fai Lee (alias: Davy) ("Mr. Lee"), aged 65, is a fellow member of The Chartered Governance Institute and The Hong Kong Chartered Governance Institute. He will also be appointed as an executive director and the Chief Executive Officer of each of LCR and HKC with effect from 7 June 2024. Mr. Lee is an authorised representative of the Company and an alternate to authorised representative of LCR and HKC. In addition, he holds directorships in certain subsidiaries of the Company and the Company's controlling shareholders. Mr. Lee had not held any directorship in listed public companies for the last three years. Mr. Lee has over 30 years' experience in treasury investments, corporate administration and company secretarial field. Mr. Lee holds a Bachelor of Arts in Chinese Humanities (First Class Honours) from The Open University of Hong Kong (now known as Hong Kong Metropolitan University), a Master of Science in Investment Management from The Hong Kong University of Science and Technology and a Doctor of Business and Administration from The Hong Kong Polytechnic University. Mr. Lee has served the Lippo group of companies for over 40 years. Mr. Lee has been the Secretary of the Company since 22 April 1991 as well as the Secretary of Lippo Capital Limited, Lippo Capital Holdings Company Limited and Lippo Capital Group Limited which have discloseable interests in the Company under the provisions of the SFO. He is also the Secretary of certain subsidiaries of the Company's controlling shareholders and the Company. Tillkännagivande • Jun 08
Lippo Limited Announces Executive and Company Secretary Changes The Board of Directors of Lippo Limited announce that Mr. John Luen Wai Lee will be re-designated from the Managing Director and Chief Executive Officer to the Deputy Chairman of the Company with effect from 7 June 2024. He remains as an executive Director of the Company. The biographical details of Mr. John Luen Wai Lee are set out below. Mr. John Luen Wai Lee, BBS, JP, aged 75, was appointed a Director of the Company on 21 March 1991. Mr. Lee is the Managing Director and Chief Executive Officer of the Company. Mr. Lee is also an executive director and the Chief Executive Officer of Lippo China Resources Limited ("LCR", a subsidiary of the Company) and Hongkong Chinese Limited ("HKC", a subsidiary of the Company), as well as an independent non-executive director of New World Development Company Limited and UMP Healthcare Holdings Limited, all are listed public companies in Hong Kong. With effect from 7 June 2024, Mr. Lee will be re-designated from the Chief Executive Officer to the Deputy Chairman of LCR and HKC. Mr. Lee is an authorised representative of the Company, LCR and HKC. In addition, he holds directorships in certain subsidiaries of the Company. Save as disclosed herein, Mr. Lee had not held any directorship in other listed public companies for the last three years. Mr. Lee is a Fellow of The Institute of Chartered Accountants in England and Wales, the Association of Chartered Certified Accountants and the Hong Kong Institute of Certified Public Accountants. He was a partner of Price Waterhouse (now known as PricewaterhouseCoopers) in Hong Kong and has extensive experience in corporate finance and capital markets. Mr. Lee is an Honorary Fellow of the City University of Hong Kong, a Justice of Peace in Hong Kong and an awardee of the Bronze Bauhinia Star by the Government of the Hong Kong Special Administrative Region. Mr. Lee is active in public service. Over the years, he served as a member or chairman of different government boards and committees in Hong Kong, including a member of the Hong Kong Hospital Authority and the Chairman of the Hospital Governing Committee of the Queen Elizabeth Hospital and Hong Kong Children's Hospital. The Board is also pleased to announce that Mr. Kwok Fai Lee will be appointed as an executive Director and the Chief Executive Officer of the Company with effect from 7 June 2024. The biographical details of Mr. Kwok Fai Lee are set out below. Mr. Kwok Fai Lee aged 65, is a fellow member of The Chartered Governance Institute and The Hong Kong Chartered Governance Institute. He will also be appointed as an executive director and the Chief Executive Officer of each of LCR and HKC with effect from 7 June 2024. Mr. Lee is an authorised representative of the Company and an alternate to authorised representative of LCR and HKC. In addition, he holds directorships in certain subsidiaries of the Company and the Company's controlling shareholders. Mr. Lee had not held any directorship in listed public companies for the last three years. Mr. Lee has over 30 years' experience in treasury investments, corporate administration and company secretarial field. Mr. Lee holds a Bachelor of Arts in Chinese Humanities (First Class Honours) from The Open University of Hong Kong (now known as Hong Kong Metropolitan University), a Master of Science in Investment Management from The Hong Kong University of Science and Technology and a Doctor of Business and Administration from The Hong Kong Polytechnic University. Mr. Lee has served the Lippo group of companies for over 40 years. Mr. Lee has been the Secretary of the Company since 22 April 1991 as well as the Secretary of Lippo Capital Limited, Lippo Capital Holdings Company Limited and Lippo Capital Group Limited which have discloseable interests in the Company under the provisions of the SFO. He is also the Secretary of certain subsidiaries of the Company's controlling shareholders and the Company. The Board announces that following the appointment of Mr. Kwok Fai Lee as an executive Director and the Chief Executive Officer of the Company, he will resign as the Company Secretary of the Company with effect from 7 June 2024. The Board also announce that Ms. Millie Yuen Fun Luk will be appointed as the Company Secretary of the Company with effect from 7 June 2024. Ms. Luk has over 30 years of experience in the legal and company secretarial fields with various listed companies and is currently the Company Secretary of LCR and HKC. She is a Chartered Secretary, a Chartered Governance Professional and a fellow member of The Chartered Governance Institute and The Hong Kong Chartered Governance Institute. Buy Or Sell Opportunity • Apr 05
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 40% to €0.075. The fair value is estimated to be €0.096, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Tillkännagivande • Mar 28
Lippo Limited, Annual General Meeting, Jun 06, 2024 Lippo Limited, Annual General Meeting, Jun 06, 2024. Reported Earnings • Mar 28
Full year 2023 earnings released: HK$0.07 loss per share (vs HK$0.25 profit in FY 2022) Full year 2023 results: HK$0.07 loss per share (down from HK$0.25 profit in FY 2022). Revenue: HK$813.5m (up 20% from FY 2022). Net loss: HK$35.4m (down 128% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings. Tillkännagivande • Mar 16
Lippo Limited to Report Fiscal Year 2023 Final Results on Mar 27, 2024 Lippo Limited announced that they will report fiscal year 2023 final results on Mar 27, 2024 New Risk • Nov 26
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.3% average weekly change). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (3.0% net profit margin). Market cap is less than US$100m (€59.6m market cap, or US$65.2m). New Risk • Oct 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.4% average weekly change). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (3.0% net profit margin). Market cap is less than US$100m (€74.2m market cap, or US$78.1m). Reported Earnings • Oct 02
First half 2023 earnings released: EPS: HK$0.005 (vs HK$0.21 in 1H 2022) First half 2023 results: EPS: HK$0.005 (down from HK$0.21 in 1H 2022). Revenue: HK$386.9m (up 23% from 1H 2022). Net income: HK$2.71m (down 97% from 1H 2022). Profit margin: 0.7% (down from 34% in 1H 2022). Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Reported Earnings • Sep 01
First half 2023 earnings released: EPS: HK$0.005 (vs HK$0.21 in 1H 2022) First half 2023 results: EPS: HK$0.005 (down from HK$0.21 in 1H 2022). Revenue: HK$386.9m (up 23% from 1H 2022). Net income: HK$2.71m (down 97% from 1H 2022). Profit margin: 0.7% (down from 34% in 1H 2022). Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. New Risk • Aug 31
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 58% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (3.0% net profit margin). Market cap is less than US$100m (€84.7m market cap, or US$91.8m). Tillkännagivande • Aug 23
Lippo Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023 Lippo Limited provided earnings guidance for the six months ended 30 June 2023. The company estimated that it may record a net fair value gain on financial instruments at fair value through profit or loss of approximately HKD 29 million for the six months ended 30 June 2023 (the "Period"), as compared to a fair value loss of HKD 25 million for the six months ended 30 June 2022 (the "Last Period"). Based on information currently available to the Company, the Board estimates that the Group may record a consolidated profit attributable to shareholders of approximately HKD 3 million for the Period, as compared to a consolidated profit of HKD 105 million for the Last Period. The change was mainly attributable to decrease in share of profit of joint ventures of the Group for the Period, but offset by the aforesaid net fair value change on financial instruments of the Group and the improvement in the performance of the Group's food businesses. Tillkännagivande • Aug 19
Lippo Limited to Report First Half, 2023 Results on Aug 30, 2023 Lippo Limited announced that they will report first half, 2023 results on Aug 30, 2023 Reported Earnings • Mar 31
Full year 2022 earnings released: EPS: HK$0.25 (vs HK$1.01 in FY 2021) Full year 2022 results: EPS: HK$0.25 (down from HK$1.01 in FY 2021). Revenue: HK$677.8m (down 6.9% from FY 2021). Net income: HK$125.3m (down 75% from FY 2021). Profit margin: 19% (down from 69% in FY 2021). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Board Change • Jan 03
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. No experienced directors. 7 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Min Yen Goh was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Tillkännagivande • Dec 13
Lippo Limited Announces Change of Independent Non-Executive Director- and Composition of Board Committees The Board of Directors of Lippo Limited announced that Mr. Neo has tendered his resignation as an independent non-executive Director of the Company with effect from 30 December 2022 and his positions as a member of each of the Audit Committee, the Remuneration Committee and the Nomination Committee of the Board will also terminate accordingly. Mr. Neo's resignation is to facilitate the gender diversity of the Board in accordancewith the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. Mr. Neo has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the Stock Exchange and the shareholders of the Company. Mr. Neo has been an independent non-executive Director of the Company since March 2002 and has served the Company and its subsidiaries (collectively, the "Group") for over 20 years. He has provided valuable service and support to the Group during his tenure of office. The Board would like to express its sincere appreciation and gratitude to Mr. Neo for his service and valuable contribution made to the Group. The Board announced that Ms. Goh has been appointed as an independent non-executive Director of the Company and a member of each of the Remuneration Committee and the Nomination Committee of the Board with effect from 30 December 2022. Ms. Goh, aged 62, obtained a Bachelor of Science in Economics and Finance with high distinction from Babson College in the United States of America. Ms. Goh is currently the managing director of Eng Wah Group and a director of Eng Wah Global Pte. Ltd. Since January 2022, Ms. Goh has been serving as an independent director and a member of each of the nominating committee and the remuneration committee of OUE Limited (a company listed on the Mainboard of Singapore Exchange Securities Trading Limited (the "SGX-ST")). Ms. Goh was a director of Eng Wah Organization Limited, which was listed on the Mainboard of SGX-ST before it was privatized in 2008. Ms. Goh has also been appointed as an independent non-executive director and a member of each of the Remuneration Committee and the Nomination Committee of the Board of both Hongkong Chinese Limited ("HKC") and Lippo China Resources Limited ("LCR") with effect from 30 December 2022. HKC and LCR are principal subsidiaries of the Company and both are listed on the Stock Exchange. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 8 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non Executive Director Victor Yung was the last independent director to join the board, commencing their role in 2004. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Tillkännagivande • Aug 24
Lippo Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022 Lippo Limited provided earnings guidance for the six months ended 30 June 2022. For the period, the company expects a consolidated profit attributable to shareholders of not less than HKD 100 million for the Period, as compared to a consolidated profit of approximately HKD 237 million for the Last Period. The decrease in profit was largely attributable to the net fair value loss on financial instruments at fair value through profit or loss of the Group during the Period while a net fair value gain was recorded in the Last Period. The impact was partially offset by the increase in share of profit of joint ventures (details of which were disclosed in the announcement of the Company dated 10 August 2022) during the Period. Tillkännagivande • Aug 19
Lippo Limited to Report First Half, 2022 Results on Aug 30, 2022 Lippo Limited announced that they will report first half, 2022 results on Aug 30, 2022 Tillkännagivande • Jun 09
Lippo Limited Approves Final Dividend for the Year Ended December 31, 2022 Lippo Limited announced at annual general meeting held on June 8, 2022, the shareholders approved to declare a final dividend of 4 HK cents per share for the year ended 31 December 2021 as recommended by the Board of Directors. Upcoming Dividend • Jun 06
Upcoming dividend of HK$0.04 per share Eligible shareholders must have bought the stock before 13 June 2022. Payment date: 29 June 2022. Payout ratio is a comfortable 3.9% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of German dividend payers (4.2%). Lower than average of industry peers (4.5%). Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 8 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non Executive Director Victor Yung was the last independent director to join the board, commencing their role in 2004. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Tillkännagivande • Apr 01
Lippo Limited, Annual General Meeting, Jun 08, 2022 Lippo Limited, Annual General Meeting, Jun 08, 2022. Agenda: To consider payment of a final dividend. Reported Earnings • Apr 01
Full year 2021 earnings released: EPS: HK$1.01 (vs HK$2.19 loss in FY 2020) Full year 2021 results: EPS: HK$1.01 (up from HK$2.19 loss in FY 2020). Revenue: HK$728.2m (down 4.7% from FY 2020). Net income: HK$500.1m (up HK$1.58b from FY 2020). Profit margin: 69% (up from net loss in FY 2020). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Tillkännagivande • Apr 01
Lippo Limited Proposes Final Dividend for the Year Ended 31 December 2021, Payable on or About 29 June 2022 The Directors of Lippo Limited have resolved to recommend to shareholders at the forthcoming Annual General Meeting to be held on Wednesday, 8 June 2022 the payment of a final dividend of 4 HK cents per share (2020 -- 3 HK cents per share) amounting to approximately HKD 19.7 million for the year ended 31 December 2021 (2020 -- approximately HKD 14.8 million). Subject to the approval of shareholders at the 2022 AGM, the final dividend will be paid on or about Wednesday, 29 June 2022 to shareholders whose names appear on the Register of Members on Friday, 17 June 2022. Ex-dividend date is 13 June 2022. Tillkännagivande • Mar 23
Lippo Limited to Report Fiscal Year 2021 Final Results on Mar 31, 2022 Lippo Limited announced that they will report fiscal year 2021 final results on Mar 31, 2022 Upcoming Dividend • Jun 03
Upcoming dividend of HK$0.03 per share Eligible shareholders must have bought the stock before 10 June 2021. Payment date: 30 June 2021. Trailing yield: 2.9%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (4.0%). Tillkännagivande • Apr 29
Lippo Limited Proposes Final Dividend for the Nine Months Ended 31 December 2020 Lippo Limited to consider and declare a final dividend of 3 Hong Kong cents per share for the nine months ended 31 December 2020 as recommended by the Board of Directors at the AGM to be held on 8 June 2021. Tillkännagivande • Mar 19
Lippo Limited to Report Nine Months, 2021 Results on Mar 30, 2021 Lippo Limited announced that they will report nine months, 2021 results on Mar 30, 2021 Is New 90 Day High Low • Feb 19
New 90-day high: €0.27 The company is up 19% from its price of €0.23 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is down 1.0% over the same period. Reported Earnings • Dec 31
First half 2021 earnings released: HK$1.30 loss per share The company reported a poor first half result with weaker earnings, revenues and control over expenses. First half 2021 results: Revenue: HK$387.4m (down 27% from 1H 2020). Net loss: HK$643.2m (down HK$735.3m from profit in 1H 2020). Over the last 3 years on average, earnings per share has fallen by 65% per year but the company’s share price has only fallen by 25% per year, which means it has not declined as severely as earnings. Upcoming Dividend • Dec 28
Upcoming Dividend of HK$0.04 Per Share Will be paid on the 27th of January to those who are registered shareholders by the 4th of January. The trailing yield of 4.0% is in the top quartile of German dividend payers (3.5%), and it is higher than industry peers (3.6%). Is New 90 Day High Low • Dec 16
New 90-day high: €0.25 The company is up 16% from its price of €0.22 on 17 September 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 1.0% over the same period. Reported Earnings • Nov 29
First half 2021 earnings released: HK$1.30 loss per share The company reported a poor first half result with weaker earnings, revenues and control over expenses. First half 2021 results: Revenue: HK$387.4m (down 27% from 1H 2020). Net loss: HK$643.2m (down HK$731.9m from profit in 1H 2020). Over the last 3 years on average, earnings per share has fallen by 65% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Nov 27
New 90-day high: €0.25 The company is up 7.0% from its price of €0.23 on 28 August 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 2.0% over the same period. Tillkännagivande • Nov 18
Lippo Limited to Report First Half, 2021 Results on Nov 27, 2020 Lippo Limited announced that they will report first half, 2021 results on Nov 27, 2020 Is New 90 Day High Low • Sep 22
New 90-day low: €0.21 The company is down 16% from its price of €0.25 on 24 June 2020. The German market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 1.0% over the same period. Tillkännagivande • Jun 17
Lippo Limited to Report Fiscal Year 2020 Results on Jun 29, 2020 Lippo Limited announced that they will report fiscal year 2020 results on Jun 29, 2020